Hwail Pharmaceutical Co.Ltd (061250) - Total Liabilities
Based on the latest financial reports, Hwail Pharmaceutical Co.Ltd (061250) has total liabilities worth ₩5.29 Billion KRW (≈ $3.58 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Hwail Pharmaceutical Co.Ltd (061250) cash conversion ratio to assess how effectively this company generates cash.
Hwail Pharmaceutical Co.Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Hwail Pharmaceutical Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 061250 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Hwail Pharmaceutical Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Hwail Pharmaceutical Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Allegiant Gold Ltd
V:AUAU
|
Canada | CA$695.03K |
|
Top High Image
TWO:3284
|
Taiwan | NT$1.40 Billion |
|
Kronos Bio Inc
NASDAQ:KRON
|
USA | $28.33 Million |
|
Metair
JSE:MTA
|
South Africa | ZAC10.13 Billion |
|
Instil Bio Inc.
NASDAQ:TIL
|
USA | $89.66 Million |
|
Airmate Cayman International Co Ltd
TW:1626
|
Taiwan | NT$5.27 Billion |
|
Botnia Gold AB (publ)
ST:BOTX
|
Sweden | Skr51.21 Million |
|
Kingston Resources Ltd
AU:KSN
|
Australia | AU$37.58 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Hwail Pharmaceutical Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hwail Pharmaceutical Co.Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 25.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hwail Pharmaceutical Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hwail Pharmaceutical Co.Ltd (2011–2024)
The table below shows the annual total liabilities of Hwail Pharmaceutical Co.Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩12.19 Billion ≈ $8.26 Million |
+5.60% |
| 2023-12-31 | ₩11.55 Billion ≈ $7.83 Million |
+15.20% |
| 2022-12-31 | ₩10.02 Billion ≈ $6.79 Million |
-19.74% |
| 2021-12-31 | ₩12.49 Billion ≈ $8.46 Million |
-2.55% |
| 2020-12-31 | ₩12.82 Billion ≈ $8.69 Million |
-35.82% |
| 2019-12-31 | ₩19.97 Billion ≈ $13.53 Million |
-9.88% |
| 2018-12-31 | ₩22.16 Billion ≈ $15.02 Million |
-13.86% |
| 2017-12-31 | ₩25.72 Billion ≈ $17.43 Million |
-10.54% |
| 2016-12-31 | ₩28.76 Billion ≈ $19.49 Million |
-30.42% |
| 2015-12-31 | ₩41.33 Billion ≈ $28.01 Million |
+22.08% |
| 2014-12-31 | ₩33.85 Billion ≈ $22.94 Million |
-7.79% |
| 2013-12-31 | ₩36.71 Billion ≈ $24.88 Million |
+18.76% |
| 2012-12-31 | ₩30.92 Billion ≈ $20.95 Million |
+5.72% |
| 2011-12-31 | ₩29.24 Billion ≈ $19.82 Million |
-- |
About Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.